STOCKHOLM--(BUSINESS WIRE)-- Regulatory News:
Medivir AB (OMX: MVIR) announces that the global second quarter net sales of Olysio (simeprevir) amounted to 831 MUSD, of which 725 MUSD were sales in the USA. Olysio continued a very positive sales development and gained market shares during the quarter.
Medivir’s royalties based on sales for the second quarter amounted to 500,7 MSEK (54,4 MEUR).
OLYSIO® global net sales Sales in MUSD Market Q2 2014 Q1 2014 US 725 291 RoW 106 63 Total global net sales MUSD 831 354
“The second quarter's royalty from Johnson & Johnson is obviously of high importance for our company. However, the biggest gain is that so many patients now can access new and effective treatments for hepatitis C, like Olysio. This really makes a difference to patients and is a powerful motivator for all of us in Medivir“, says Maris Hartmanis, Medivir’s CEO.
Medivir will publish its second quarter report on August 21, 2014 at 8.30 CET followed by a conference call for investors, analysts and the media at 14.00 CET. More information about the conference call / audiocast will be available at www.Medivir.com.
Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.55 CET on 15 July 2014.
Olysio is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis.
Janssen is responsible for the global clinical development of Olysio and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for Olysio in these countries under the marketing authorization held by Janssen-Cilag International NV. Olysio was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis in September 2013 in Japan, in November 2013 in Canada and the U.S. and in March 2014 in Russia. Following the EMA approval, it is anticipated that Olysio will be available across a number of European Union countries in conjunction with reimbursement, in the second half of 2014. Olysio (simeprevir) is marketed under the trade name Sovriad® in Japan and Russia, Galexos™ in Canada and Olysio® in the U.S. and European Union.
Medivir (STO:MVIR-B) is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is Olysio, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.
This information was brought to you by Cision http://news.cision.com
Rein Piir, EVP
Corporate Affairs & IR
mobile: +46 708 537 292